|
| | Publication Year | Title | Author(s) |
| 1 | 13-Feb-2024 | Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma. | Wai, Shin Hnin; Lee, Sze Ting ; Cliff, Edward Robert Scheffer; Bei, Michael; Lee, Jiwoo; Hawkes, Eliza A ; Chong, Geoffrey |
| 2 | 16-Jan-2024 | Positron Emission Tomography/Computed Tomography Transformation of Oncology: Melanoma and Skin Malignancies. | Lee, Sze Ting ; Kovaleva, Natalia; Senko, Clare ; Kee, Damien ; Scott, Andrew M |
| 3 | Jan-2024 | Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. | Hofman, Michael S; Emmett, Louise; Sandhu, Shahneen; Iravani, Amir; Buteau, James P; Joshua, Anthony M; Goh, Jeffrey C; Pattison, David A; Tan, Thean Hsiang; Kirkwood, Ian D; Ng, Siobhan; Francis, Roslyn J; Gedye, Craig; Rutherford, Natalie K; Weickhardt, Andrew J ; Scott, Andrew M ; Lee, Sze Ting ; Kwan, Edmond M; Azad, Arun A; Ramdave, Shakher; Redfern, Andrew D; Macdonald, William; Guminski, Alex; Hsiao, Edward; Chua, Wei; Lin, Peter; Zhang, Alison Yan; Stockler, Martin R; Williams, Scott G; Martin, Andrew J; Davis, Ian D |
| 4 | 7-Dec-2023 | FDG-PET/CT for investigation of pyrexia of unknown origin: a cost of illness analysis. | Liu, Bonnia ; Ma, Ronald ; Shum, Evonne; Hormiz, Maria; Lee, Sze Ting ; Poon, Aurora M T ; Scott, Andrew M |
| 5 | 6-Dec-2023 | Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer. | Buteau, James P; Moon, Daniel; Fahey, Michael T; Roberts, Matthew J; Thompson, James; Murphy, Declan G; Papa, Nathan; Mitchell, Catherine; De Abreu Lourenco, Richard; Dhillon, Haryana M; Kasivisvanathan, Veeru; Francis, Roslyn J; Stricker, Phillip; Agrawal, Shihka; O'Brien, Jonathan; McVey, Aoife ; Sharma, Gaurav; Levy, Sidney; Ayati, Narjess ; Nguyen, Andrew; Lee, Su-Faye; Pattison, David A; Sivaratnam, Dinesh; Frydenberg, Mark; Du, Yang; Titus, Jehan; Lee, Sze Ting ; Ischia, Joseph J ; Jack, Greg; Hofman, Michael S; Emmett, Louise |
| 6 | Nov-2023 | Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06. | Barry, Nathaniel; Francis, Roslyn J; Ebert, Martin A; Koh, Eng-Siew; Rowshanfarzad, Pejman; Hassan, Ghulam Mubashar; Kendrick, Jake; Gan, Hui K ; Lee, Sze Ting ; Lau, Eddie ; Moffat, Bradford A; Fitt, Greg ; Moore, Alisha; Thomas, Paul; Pattison, David A; Akhurst, Tim; Alipour, Ramin; Thomas, Elizabeth L; Hsiao, Edward; Schembri, Geoffrey P; Lin, Peter; Ly, Tam; Yap, June; Kirkwood, Ian; Vallat, Wilson; Khan, Shahroz; Krishna, Dayanethee; Ngai, Stanley; Yu, Chris; Beuzeville, Scott; Yeow, Tow C; Bailey, Dale; Cook, Olivia; Whitehead, Angela; Dykyj, Rachael; Rossi, Alana; Grose, Andrew; Scott, Andrew M |
| 7 | 4-Aug-2023 | [18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial. | Koh, Eng-Siew; Gan, Hui K ; Senko, Clare ; Francis, Roslyn J; Ebert, Martin; Lee, Sze Ting ; Lau, Eddie ; Khasraw, Mustafa; Nowak, Anna K; Bailey, Dale L; Moffat, Bradford A; Fitt, Gregory J ; Hicks, Rodney J; Coffey, Robert; Verhaak, Roel; Walsh, Kyle M; Barnes, Elizabeth H; De Abreu Lourenco, Richard; Rosenthal, Mark; Adda, Lucas; Foroudi, Farshad ; Lasocki, Arian; Moore, Alisha; Thomas, Paul A; Roach, Paul; Back, Michael; Leonard, Robyn; Scott, Andrew M |
| 8 | May-2023 | Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study. | Manos, Kate ; Chong, Geoffrey ; Keane, Colm; Lee, Sze Ting ; Smith, Charmaine; Churilov, Leonid ; McKendrick, Joseph; Renwick, William; Blombery, Piers; Burgess, Melinda; Nelson, Niles Elizabeth; Fancourt, Tineke ; Hawking, Joanne; Lin, Wendi; Scott, Andrew M ; Barraclough, Allison ; Wight, Joel C ; Grigg, Andrew P ; Fong, Chun Yew ; Hawkes, Eliza A |
| 9 | 2023 | Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas. | Loo, Sun; Lim, Andrew Boon Ming ; Lee, Sze Ting ; Grigg, Andrew P |
| 10 | Nov-2022 | PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. | Buteau, James P; Martin, Andrew J; Emmett, Louise; Iravani, Amir; Sandhu, Shahneen; Joshua, Anthony M; Francis, Roslyn J; Zhang, Alison Y; Scott, Andrew M ; Lee, Sze Ting ; Azad, Arun A; McJannett, Margaret M; Stockler, Martin R; Williams, Scott G; Davis, Ian D; Hofman, Michael S |
| 11 | Oct-2022 | Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance. | Hapgood, Greg; Latimer, Maya; Lee, Sze Ting ; Kuss, Bryone; Lade, Stephen; Tobin, Joshua W D; Purtill, Duncan; Campbell, Belinda A; Prince, H Miles; Hawkes, Eliza A ; Shortt, Jake; Radeski, Dejan |
| 12 | Sep-2022 | Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. | Wight, Joel C ; Hamad, Nada; Campbell, Belinda A; Ku, Matthew; Lee, Kenneth; Rose, Hannah; Armytage, Tasman; Latimer, Maya; Lee, Hui-Peng; Lee, Sze Ting ; Dickinson, Michael; Khor, Richard ; Verner, Emma |
| 13 | 6-Aug-2022 | The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review. | Kiamanesh, Zahra; Ayati, Narjess ; Sadeghi, Ramin; Hawkes, Eliza A ; Lee, Sze Ting ; Scott, Andrew M |
| 14 | Aug-2022 | A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers. | Gan, Hui K ; Parakh, Sagun ; Lee, Fook-Thean; Tebbutt, Niall C ; Ameratunga, Malaka; Lee, Sze Ting ; O'Keefe, Graeme J; Gong, Sylvia J; Vanrenen, Christine; Caine, Jaren; Giovannetti, Mara; Murone, Carmel ; Scott, Fiona E; Guo, Nancy; Burvenich, Ingrid J G; Paine, Cameron; Macri, Mary J; Kotsuma, Masakatsu; Senaldi, Giorgio; Venhaus, Ralph; Scott, Andrew M |
| 15 | Jun-2022 | The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective. | Lee, Sze Ting ; Emmett, Louise M; Pattison, David A; Hofman, Michael S; Bailey, Dale L; Latter, Melissa J; Francis, Roslyn J; Scott, Andrew M |
| 16 | 11-Mar-2022 | Radiolabeled Antibodies for Cancer Imaging and Therapy. | Parakh, Sagun ; Lee, Sze Ting ; Gan, Hui K ; Scott, Andrew M |
| 17 | Feb-2022 | Radiotherapy planning of lymphomas: role of metabolic imaging with PET/CT. | McKay, Michael J; Taubman, Kim L; Lee, Sze Ting ; Scott, Andrew M |
| 18 | 2022 | Impact of 18F-FDG PET/CT on treatment of patients with differentiated thyroid carcinoma, negative 131I whole body scan and elevated serum thyroglobulin. | Boktor, Raef R; Lee, Sze Ting ; Berlangieri, Salvatore U ; Scott, Andrew M |
| 19 | 20-Oct-2021 | Diagnosis, management and follow up of peripheral T cell lymphomas: A Consensus Practice Statement from the Australasian Lymphoma Alliance. | Hapgood, G; Latimer, M; Lee, Sze Ting ; Kuss, B; Lade, S; Tobin, J W D; Purtill, D; Campbell, B A; Prince, H M; Hawkes, Eliza A ; Shortt, J; Radeski, D |
| 20 | 16-Sep-2021 | Diffuse large B-cell lymphoma: A consensus practice statement from the Australasian Lymphoma Alliance. | Wight, Joel C ; Hamad, N; Campbell, B A; Ku, M; Lee, K; Rose, H; Armytage, T; Latimer, M; Lee, H P; Lee, Sze Ting ; Dickinson, M; Khor, Richard ; Verner, E |
Loading...
2
0
20
0
false
0000-0001-8641-456x